#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14142	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2117	663.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1390	1390	C	803	C	754	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25972	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	721.6	0	.	n	.	0	T695C	SNP	695	695	T	1032	1032	C	779	C,A,T	728,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25972	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	721.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1674	1674	A	910	A	854	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25972	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	721.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2308	2308	C	857	C	807	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25972	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	721.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2382	2382	A	803	A	753	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25972	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	721.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2934	2934	C	830	C	784	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25972	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3587	721.6	0	HET	.	.	.	A2404G	.	2404	2404	A	2741	2741	A	846	A,G	608,185	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2000	folP	852	852	100.0	folP.l15.c30.ctg.1	1566	127.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1055	1057	AGC	224;221;220	A;G;C	213;209;208	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5108	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3587	142.0	1	SNP	p	S91F	0	.	.	271	273	TCC	753	755	TCC	184;185;186	T;C;C	173;171;172	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5108	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3587	142.0	1	SNP	p	D95G	0	.	.	283	285	GAC	765	767	GAC	178;178;180	G;A;C	165;163;166	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5108	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3587	142.0	1	SNP	p	D95N	0	.	.	283	285	GAC	765	767	GAC	178;178;180	G;A;C	165;163;166	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1612	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1341	119.9	1	SNP	p	G45D	0	.	.	133	135	GGC	418	420	GGC	206;209;206	G;G;C	192;195;196	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	844	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1140	73.8	0	.	n	.	0	A197.	DEL	197	197	A	613	613	A	197	A	185	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5106	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2937	173.3	1	SNP	p	D86N	0	.	.	256	258	GAC	548	550	GAC	207;207;206	G;A;C	189;191;193	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5106	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2937	173.3	1	SNP	p	S87R	0	.	.	259	261	AGT	551	553	AGT	208;202;202	A;G;T	192;190;190	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5106	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2937	173.3	1	SNP	p	S87W	0	.	.	259	261	AGT	551	553	AGT	208;202;202	A;G;T	192;190;190	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5106	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2937	173.3	1	SNP	p	S87I	0	.	.	259	261	AGT	551	553	AGT	208;202;202	A;G;T	192;190;190	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5106	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2937	173.3	1	SNP	p	S88P	0	.	.	262	264	TCC	554	556	TCC	200;202;200	T;C,A;C	190;191,1;188	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4372	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2735	159.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1576	1578	GGC	215;214;215	G,T;G;C	200,1;198;200	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1182	1184	GCA	220;219;223	G;C;A	203;201;209	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1185	1187	ATC	224;222;221	A;T;C	208;207;206	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1197	1199	GTG	216;214;215	G;T,C;G	202;195,1;197	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1197	1199	GTG	216;214;215	G;T,C;G	202;195,1;197	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1701	1703	ACC	176;176;174	A;C;C	158;161;161	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1755	1757	GCG	185;184;184	G;C;G	169;158;159	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1755	1757	GCG	185;184;184	G;C;G	169;158;159	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1878	1880	GGC	170;170;169	G;G;C	164;160;160	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1887	1889	GGC	169;163;161	G;G;C	160;152;147	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3846	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2291	167.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1905	1907	CCG	137;140;141	C,G;C;G	111,2;113;117	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5308	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3189	166.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1667	1669	CTG	210;210;209	C;T,C;G	186;189,1;191	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2406	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1810	132.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	573	573	C	143	C	130	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2474	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1537	160.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	425	427	GGA	217;218;217	G;G;A	196;197;196	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2474	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1537	160.1	0	.	p	.	0	F135L	NONSYN	403	405	TTT	686	688	CTT	171;174;170	C;T;T	163;166;163	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2474	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1537	160.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	710	712	GGA	173;174;174	G,C;G,A;A	161,1;162,1;160	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2474	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1537	160.1	0	.	p	.	0	D171G	NONSYN	511	513	GAT	794	796	GGT	190;193;195	G;G;T	174;177;174	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2474	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1537	160.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	848	850	AGC	197;194;190	A,G;G;C	177,1;177;174	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2474	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1537	160.1	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	914	914	T	166	T	153	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2474	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1537	160.1	1	SNP	p	G120K	0	.	.	358	360	GGT	641	643	GGT	170;168;172	G;G;T	151;151;153	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2474	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1537	160.1	1	SNP	p	A121N	0	.	.	361	363	GCC	644	646	GCC	171;171;173	G;C;C	154;155;155	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2474	porB1b	1035	1035	95.82	porB1b.l6.c4.ctg.1	1537	160.1	1	SNP	p	A121D	0	.	.	361	363	GCC	644	646	GCC	171;171;173	G;C;C	154;155;155	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9484	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4806	196.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1983	1985	AAT	221;222;224	A;A;T	213;212;210	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1064	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1216	87.4	1	SNP	p	V57M	1	.	.	169	171	ATG	635	637	ATG	219;217;216	A;T;G	208;205;203	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
